5-Hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptors stimulate [S-35]guanosine-5'-O-(3-thio)triphosphate binding to rodent brain sections as visualized by in vitro autoradiography

被引:61
作者
Waeber, C
Moskowitz, MA
机构
[1] Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Charlestown
[2] Massachusetts General Hospital, CNY149, Charlestown, MA 02129
关键词
D O I
10.1124/mol.52.4.623
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
[S-35]Guanosine-5'-O-(3-thio)triphosphate ([S-35]GTP gamma S) binding to G proteins was measured by in vitro autoradiography in guinea pig and rat brain sections after activation by 5-hydroxytryptamine (5-HT) receptor agonists. 5-Carboxamidotryptamine stimulated binding strongly in hippocampus and lateral septum and weakly in substantia nigra. This effect was blocked in the substantia nigra by the 5-HT1B/1D receptor antagonist GR-127,935 and in the former two regions by the 5-HT1A antagonist NAN-190. 5-HT1B/1D receptor agonists stimulated binding in substantia nigra and in areas containing 5-HT1A receptors. In guinea pig substantia nigra, 5-(nonyloxy)-tryptamine maximally stimulated [S-35]GTP gamma S binding by 54%, with an EC50 value of 62 nM; at 100 mu M, this agonist increased binding by similar to 200% in hippocampus (with a 2-fold weaker EC50 value). The distribution of [H-3]8-OH-DPAT binding sites was identical to that of the [S-35]GTP gamma S labeling stimulated by the 5-HT1A agonist (R)-8-hydroxy-2-dipropylaminotetralin [(R)-8-OH-DPAT)]. (R)-8-OH-DPAT, (S)-8-OH-DPAT, and buspirone stimulated [S-35]GTP gamma S binding in hippocampus by 340%, 140%, and 78%, with EC50 values of 71, 51, and 132 nM. Enhanced [S-35]GTP gamma S binding was not detected in the presence of 5-HT1F, 5-HT2, 5-HT4, and 5-HT7 receptor agonists, Because activation of mu-opioid, muscarinic M-2, histamine H-3, and cannabinoid receptors was also visualized successfully, these data suggest that only receptors coupled to pertussis toxin-sensitive G proteins can be seen by [S-35]GTP gamma S binding autoradiography. This study also shows that different 5-HT receptors coupled to these proteins can show a wide range of [S-35]GTP gamma S binding stimulation. Although the functional significance of these variations is unclear, this technique offers advantages over receptor autoradiography because it does not require high affinity radioligands and provides a measure of agonist efficacies in various brain regions.
引用
收藏
页码:623 / 631
页数:9
相关论文
共 30 条
[11]   5-(NONYLOXY)TRYPTAMINE - A NOVEL HIGH-AFFINITY 5-HTID-BETA SEROTONIN RECEPTOR AGONIST [J].
GLENNON, RA ;
HONG, SS ;
DUKAT, M ;
TEITLER, M ;
DAVIS, K .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (18) :2828-2830
[12]   [H-3] L-694,247 LABELS THE 5-HT1D-BETA RECEPTOR IN PIG CAUDATE MEMBRANES [J].
HEALD, A ;
STANTON, JA ;
OSBORNE, SA ;
MIDDLEMISS, DN ;
BEER, MS .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 264 (02) :213-216
[13]  
HOYER D, 1994, PHARMACOL REV, V46, P157
[14]  
KOWAL DM, 1996, SOC NEUR ABSTR, V22
[15]  
KURKINEN K, 1996, SOC NEUR ABSTR, V22
[16]  
LORENZEN A, 1993, MOL PHARMACOL, V44, P115
[17]   5-[(3-NITROPYRID-2-YL)AMINO]INDOLES - NOVEL SEROTONIN AGONISTS WITH SELECTIVITY FOR THE 5-HT1D RECEPTOR - VARIATION OF THE C3 SUBSTITUENT ON THE INDOLE TEMPLATE LEADS TO INCREASED 5-HT1D RECEPTOR SELECTIVITY [J].
MACOR, JE ;
BLANK, DH ;
FOX, CB ;
LEBEL, LA ;
NEWMAN, ME ;
POST, RJ ;
RYAN, K ;
SCHMIDT, AW ;
SCHULZ, DW ;
KOE, BK .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (16) :2509-2512
[18]   S 15535 and WAY 100,635 antagonise 5-HT-stimulated [S-35]GTP gamma S binding at cloned human 5-HT1A receptors [J].
NewmanTancredi, A ;
Chaput, C ;
Verriele, L ;
Millan, MJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 307 (01) :107-111
[19]   G(ALPHA-O1) DECAPEPTIDE MODULATES THE HIPPOCAMPAL 5-HT1A POTASSIUM CURRENT [J].
OLESKEVICH, S .
JOURNAL OF NEUROPHYSIOLOGY, 1995, 74 (05) :2189-2193
[20]   How efficacious are 5-HT1B/D receptor ligands: An answer from GTP gamma S binding studies with stably transfected C6-glial cell lines [J].
Pauwels, PJ ;
Tardif, S ;
Palmier, C ;
Wurch, T ;
Colpaert, FC .
NEUROPHARMACOLOGY, 1997, 36 (4-5) :499-512